The book opens with a section devoted to three Fc-dependent mechanisms that are crucial to immunity: 1) antibody-dependent cellular cytotoxicity (ADCC); 2) antibody-dependent cellular phagocytosis (ADCP); and 3) complement-dependent cytotoxicity (CDC). **Victor Raúl Gómez Román**, **Joseph C. Murray** and **Louis M. Weiner** discuss ADCC, and set the stage for subsequent chapters, by first introducing two crucial elements of the immune system, effector cells and the Fcγ receptors (FcγR) expressed on them. The authors then explain in detail the sequential steps of ADCC, including crosslinking of target and effector cells, downstream signaling in the effector cell and killing of the target cell, which can be achieved via various pathways. The roles of ADCC in cancer therapy (e.g., rituximab, cetuximab, trastuzumab, panitumumab treatment), and in protection from infectious disease are considered. The authors note that enhancement of ADCC mediated by monoclonal antibodies (mAbs) can be achieved via glyco- or protein-engineering of the Fc region, but a wide variety of other mechanisms of action can also be utilized by mAb therapeutics.

ADCP and its impact on pathogen control are examined by **Stefan S. Weber** and **Annette Oxenius**. The process of phagocytosis involves the active uptake and endocytosis of particles larger than 0.5 μm (e.g., antibody-containing immune complexes) into FcγR-expressing cells such as monocytes, macrophages, neutrophils and dendritic cells. The FcγRs are differentially expressed on the cells in a dynamic fashion that is regulated by the cytokine milieu. With this as introduction, the authors then discuss the role of FcγR-mediated phagocytosis for the uptake, cellular localization and control of pathogens, including bacteria, viruses, parasites and fungi. Evasion strategies developed by pathogens and the phenomenon of antibody-dependent enhancement (ADE) of infection are also presented.

The complex interactions between the complement system and FcγRs are explored by **Margaret A. Lindorfer**, **Jörg Köhl** and **Ronald P. Taylor**. They first describe the CDC process, which involves complement activation by immune complex, opsonization, immobilization of the complex via complement receptor 1 (CR1; cognate ligand is C3b) on erythrocytes and, finally, transfer to acceptor cells (e.g., monocytes, macrophages) via their FcγRs. Interestingly, B cells can engage in a similar process, although immobilization of the complex occurs via CR2 (cognate ligand is C3d) expressed on B cells. The authors present the different processing reactions of immune complexes in the context of infection by human immunodeficiency virus (HIV), emphasizing that a possible outcome is infection of the acceptor cell. Cooperation/synergy between FcγRs and CRs, in particular FcγRIII and CR3, on effector cells and cross-talk between the C5a receptor and FcγR on effector cells are discussed in detail. The authors conclude by remarking on the challenges of developing therapeutics that appropriately regulate the two effector systems.

Section 2 focuses on three types of cells that are crucial to the immune system, natural killer (NK) cells, phagocytes and B cells. **Andreas Diefenbach** presents the role of NK cells in the innate immune response and emphasizes the complex interplay of inhibitory input (e.g., from killer cell immunoglobulin-like receptors) and activating input (e.g., from FcγRIIIa, NKG2D) that regulates their activity. The author also highlights recent work that has identified adaptive features of NK cells, such as priming and memory. The interactions of phagocytes and immunoglobulins are examined by **Luisa Martinez-Pomares**. The author introduces general characteristics of mononuclear phagocytes (macrophages, dendritic cells, monocytes) and granulocytes (neutrophils, eosinophils, basophils), and discusses in detail the mechanisms by which these cells recognize antigens, which may or may not be opsonized, and the phagocytosis process. The importance of the interplay between activating FcR, inhibiting FcR and pattern-recognition receptors, which are non-opsonic receptors, in the function and regulation of phagocytes is emphasized. B cell development, differentiation and regulation in the humoral immune response are examined by **Elizabeth R. Walsh** and **Silvia Bolland**. In particular, the authors provide details of the role of FcγRIIb, which has inhibitory activity, in regulating B cell activation and apoptosis, inhibiting auto-antibody production and regulating long-term survival of plasma cells in the bone marrow. These roles suggest the potential of FcγRIIb as a target for therapies for diseases characterized by dysregulation of IgG antibodies and plasma cells.

Fc receptors are the topic of two chapters in Section 3. The intricacies of structural recognition of the immunoglobulin Fc by FcγRs are revealed by **Peter Sun**. After introducing the relevant structures, the author discusses the specificities of FcγRs for IgG subclasses, the influence of FcR polymorphism on IgG recognition and the role of Fc glycosylation in the recognition of antibodies by FcγRs. The interaction of FcRs with pentraxins, which are pattern-recognition proteins that can opsonize antigens, is also examined. **Brian Moldt** and **Ann J. Hessell** provide a detailed analysis of FcγRs across species. The structure, expression and functions of human FcγRs are compared and contrasted to those of mouse and macaque. The authors highlight the appreciable differences, which reinforce the need for caution when translating results from animal models to development programs for human therapeutics.

Two chapters in Section 4 focus on variability in the Fc domain. The unique features of the four human IgG subclasses are examined by **Theo Rispens** and **Gestur Vidarsson**. Differences in the IgG isotype structures (e.g., variation in the hinge region, disulfide bonds, susceptibility to proteolysis) and their binding to effector molecules (e.g., C1q, FcγRs) are detailed. The authors also delineate the circumstances under which class switching occurs, which allows the most effective antibody responses to protein, polysaccharide or viral antigens, as well as allergens. **Xiaojie Yu**, **Kavitha Baruah**, **Christopher N. Scanlan** and **Max Crispin** discuss antibody glycosylation. The roles of glycosylation in antibodies overall, and the IgG Fc structure in particular, are explored. The authors then examine differences in the activities of IgG glycoforms, including the effects of deglycosylation and changes in the levels of glycans (e.g., fucose, galactose, sialic acid, mannose) that are present. The potential for manipulation of antibody glycans by humans (e.g., to engineer more effective therapeutic antibodies) or pathogens (e.g., to evade the immune system) is explored.

Section 5 focuses on genetic associations between the components of the immune system and disease, emphasizing the delicate balance that is needed between immune responses that are appropriately strong and long, but specific and controlled. The roles of activating and inhibitory FcγRs in autoimmune disorders such as systemic lupus erythematosus are presented by **Falk Nimmerjahn**. The signaling pathways of activating receptors vs. those of FcγRIIb are delineated within the context of co-expression of the receptors on effector cells. The author discusses in detail the expression of FcγRIIb on B cells and the effects of changes in expression, FcγRIIb as a regulator of dendritic activity and the role of FcγRIIb in controlling innate immune effector cell activation. **Menna R. Clatworthy** examines Fcγ receptor polymorphisms, such as FcγRIIA-H131R, and susceptibility to infections. The FcγR family genes and genetic variation in the receptors are first presented, then the author discusses the roles of FcγR in the defense against infection by Gram-positive and Gram-negative bacteria (e.g., *Streptococcus pneumoniae*, *Streptococcus aureus*, *Hemophilus influenza*, *Neisseria meningitides*, *Bordatella perussis*), viruses (Dengue virus, poliovirus, human herpesvirus 8, influenza virus, HIV), and parasites (malarial parasites, *Brugia malayi*). The role of IgG Fc receptors in mAb therapy of cancer is explored by **Marije B. Overdijk**, **Sandra Verploegen**, **Wim K. Bleeker** and **Paul W.H.I. Parren**. They examine the preclinical and clinical data for mAbs used as cancer treatments (rituximab, ofatumumab, trastuzumab, cetuximab and alemtuzumab) that support roles for FcγR-mediated effector function, and elucidate the effects of FcγR polymorphisms on treatment with mAbs. Strategies to optimize FcγR-mediated effector functions are also discussed.

The seven chapters in the final section of the book are devoted to examination of evolving areas. In the chapter "No mechanism is an island," **George J. Weiner** outlines the interactions among mAb mechanisms of action, noting what is and is not known based on in vitro studies, animal models and clinical studies. The limitations of non-clinical study results are delineated, and individual, synergistic and antagonistic mechanisms are discussed. **Joseph U. Igietseme**, **Xiaoping Zhu** and **Carolyn M. Black** examine FcR-dependent immunity, and include FcR-independent functions of antibodies as context. Fcγ receptors as therapeutic targets are examined by **Robert M. Anthony**. The implications of affecting activating or inhibiting FcRs in the treatment of cancer, immune-mediated disorders or infection are discussed. **Roy Jefferis** evaluates the effects of IgG-Fc protein engineering, with detailed discussion of various engineered IgG isotypes and the consequences of their binding to FcγRs and FcRn. Enhancement of complement activation via Fc protein engineering is also examined.

Bacterial modulation of Fc effector functions are explored by **Mattias Collin** and **Mogens Kilian**. The authors describe the numerous and varied ways in which bacterial proteins (e.g., IgG-binding proteins, proteases, glycan hydrolases) subvert Fc-mediated functions of the immune system via modification of antibodies. The utility of some of the proteins (e.g., Protein A, EndoS, IdeS) as tools in antibody characterization and their potential as therapeutics are noted. **Scott B. Halstead** examines the pathogenic exploitation of Fc activity, focusing on ADE. As discussed by the author, this phenomenon, whereby cross-linking of immune complexes and FcγRs leads to infection of cells such as macrophages, is known to occur in infection by viruses (e.g., Dengue) and protozoan parasites (e.g., *Leishmania*). ADE in infection by other intracellular parasites and bacteria is also considered. In the last chapter, **Shannon A. Allen** and **Thomas J. Hope** discuss the mechanisms of immunoglobulin-mediated mucus entrapment of pathogens at various mucosal surfaces, with emphasis on the roles of both IgG and IgA.

*Antibody Fc: Linking Adaptive and Innate Immunity* is highly recommended reading for all students of immunology and scientists involved in the research and development of therapeutic antibodies and vaccines because of its comprehensive coverage of relevant topics. Inevitable redundancies occur, with numerous chapters including descriptions of the structure and function of IgG isotypes and FcγRs, but these serve to reinforce valuable points and allow each chapter to be understood independently of the others. The book is also recommended as an excellent resource for academic, government and company libraries.
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